newsfilter
← Latest News
GlobeNewswire·

Telomir Announces Research with The Ohio State University Demonstrating In-Vitro Anti-Cancer Activity in Human and Canine Osteosarcoma Models

TELO
  • Telomir Pharmaceuticals announced that Telomir-Zn inhibited cell growth across human (HOS) and canine (D17, Abrams) osteosarcoma cell line models in research conducted at The Ohio State University College of Veterinary Medicine.
  • The study demonstrated dose-dependent anti-tumor activity at similar low drug concentrations for all three models, validating the therapeutic potential of the compound in naturally occurring disease settings.
  • Telomir is assessing a strategic pathway to develop Telomir-Zn for canine osteosarcoma, which could accelerate translational research for both veterinary patients and humans due to biological similarities between the species.
  • The company's primary TNBC program remains the immediate focus, advancing toward site initiation & Phase 1/2 patient enrollment under an FDA-cleared IND for advanced or metastatic triple-negative breast cancer.
  • Telomir-Zn functions by targeting intracellular iron & copper homeostasis to disrupt labile iron pools & inhibit iron-dependent histone demethylases, thereby reversing cancer-associated epigenetic silencing.
  • Chairman & CEO Erez Aminov stated that this multi-pronged approach across TNBC & potential osteosarcoma indications could establish Telomir-Zn as a platform therapy for aggressive malignancies.
  • The press release includes standard forward-looking statements regarding development plans, regulatory pathways, & potential risks associated with clinical trials & market conditions.